I believe the FDA is making a decision next month.
I think the editorial editorial summed up the findings and out look "... the therapeutic gain, with the rates of response to treatment (i.e., adequate relief) ranging between 9 and 12% more with rifaximin than with placebo, is in the lower spectrum of what is considered to be clinically relevant."
-------------------- STABLE: ♂, IBS-D 50+ years - Science of IBS
Posts
Re: New Xifaxan 550 Study - Approval Date for IBS-D 3/7/2011
